Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.
2.

Incidental findings on follow-up fluorodeoxyglucose positron emission tomography studies in lymphoma patients: beware the outlier.

Aide N, Irving L, Hicks RJ.

Leuk Lymphoma. 2009 Jun;50(6):865-7. doi: 10.1080/10428190903030866. No abstract available.

PMID:
19504393
3.

Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.

Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J.

Leuk Lymphoma. 2008 Sep;49(9):1778-83. doi: 10.1080/10428190802270886.

PMID:
18798110
4.

Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma.

Yamane T, Daimaru O, Ito S, Nagata T, Yoshiya K, Fukaya N, Ito S, Imai T, Uchida H.

Ann Nucl Med. 2008 Oct;22(8):719-22. doi: 10.1007/s12149-008-0183-7. Epub 2008 Nov 4.

PMID:
18982476
5.

A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.

Falchi L, Capello D, Palumbo B, Rauco A, Emili R, Cianciulli M, Pace R, Capparella V, Liberati F, Liberati AM.

Eur J Haematol. 2007 Nov;79(5):455-61. Epub 2007 Oct 1.

6.

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.

De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M.

J Clin Oncol. 2009 Jul 10;27(20):3303-11. doi: 10.1200/JCO.2008.19.4423. Epub 2009 May 18.

PMID:
19451443
7.

[18F]2-fluoro-2-deoxyglucose positron emission tomography/computed tomography in predicting radiation pneumonitis.

Song H, Yu JM, Kong FM, Lu J, Bai T, Ma L, Fu Z.

Chin Med J (Engl). 2009 Jun 5;122(11):1311-5.

PMID:
19567143
8.

Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.

Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, de Klerk JM, Oyen WJ, Meijer S, Hoekstra HJ.

J Clin Oncol. 2009 Oct 1;27(28):4774-80. doi: 10.1200/JCO.2008.20.1822. Epub 2009 Aug 31.

PMID:
19720925
9.

Sciatic nerve neurolymphomatosis - extent and therapy response assessment with PET/CT.

Strobel K, Fischer K, Hany TF, Poryazova R, Jung HH.

Clin Nucl Med. 2007 Aug;32(8):646-8.

PMID:
17667443
10.

The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.

Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O.

Ann Hematol. 2011 Feb;90(2):165-71. doi: 10.1007/s00277-010-1044-8. Epub 2010 Aug 13.

PMID:
20706721
11.

Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment.

Jerushalmi J, Frenkel A, Bar-Shalom R, Khoury J, Israel O.

J Nucl Med. 2009 Jun;50(6):849-53. doi: 10.2967/jnumed.108.058586. Epub 2009 May 14.

12.

Grade I lymphomatoid granulomatosis with increased uptake of [18F] fluorodeoxyglucose in positron emission tomography: a case report.

Arai H, Oshiro H, Yamanaka S, Yukawa N, Wada N, Rino Y, Watanuki Y, Yamanaka S, Inayama Y, Lee J, Nakayama H, Masuda M.

J Clin Exp Hematop. 2009 May;49(1):39-44. Review.

13.

PET/CT for therapy response assessment in lymphoma.

Hutchings M, Barrington SF.

J Nucl Med. 2009 May;50 Suppl 1:21S-30S. doi: 10.2967/jnumed.108.057190. Epub 2009 Apr 20. Review.

14.

Comparison of 18F-FDG positron emission tomography and computed tomography in patients with colorectal carcinoma and lymphoma: our initial clinical experience.

Coha B, Radmilović K, Gardasanić J, Daković M, Stefanić M, Latić A, Mitrecić D.

Acta Clin Croat. 2009 Mar;48(1):35-9.

PMID:
19623870
15.

[Interstitial pneumonitis as a side effect of rituximab].

Kemming JL, van Zeeland RE, Ullmann EF, Mattijssen EJ.

Ned Tijdschr Geneeskd. 2009;153:A526. Dutch.

PMID:
19785875
16.

A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.

Bishton MJ, Hicks RJ, Westerman DA, Prince MH, Wolf M, Seymour JF.

Haematologica. 2008 May;93(5):789-90. doi: 10.3324/haematol.12253. No abstract available.

17.

[Rituximab in the treatment of indolent non-Hodgkin's lymphoma].

Aurer I, Mitrović Z, Radman I, Kovacević-Metelko J, Nemet D, Serventi-Seiwerth R, Stern-Padovan R, Jakic-Razumović J, Nola M, Zupancić-Salek S, Sertić D, Labar B.

Lijec Vjesn. 2004 Nov-Dec;126(11-12):307-11. Croatian.

PMID:
16082888
18.

Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer.

Bae JS, Chae BJ, Park WC, Kim JS, Kim SH, Jung SS, Song BJ.

World J Surg Oncol. 2009 Aug 10;7:63. doi: 10.1186/1477-7819-7-63.

19.

Giant cell arteritis on 18F-FDG PET/CT.

Heston TF, Szabo Z.

Clin Physiol Funct Imaging. 2009 Sep;29(5):382-4. doi: 10.1111/j.1475-097X.2009.00881.x. Epub 2009 Jun 11.

PMID:
19522856
20.

Features of large cell transformation of indolent lymphomas as observed on sequential PET/CT.

Karam M, Feustel PJ, Vera CD, Nazeer T.

Nucl Med Commun. 2011 Mar;32(3):177-85. doi: 10.1097/MNM.0b013e328342b9d2.

PMID:
21169873

Supplemental Content

Support Center